METHOD OF DETERMINING POLYMORPHIC MARKERS IN CYP2C19 AND CYP2D6 GENES FOR DETERMINING INDIVIDUAL SENSITIVITY TO ANTIDEPRESSANTS Russian patent published in 2020 - IPC C12Q1/68 

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology. Functional activity of cytochrome CYP2C19 and CYP2D6 cytoplasm are largely due to polymorphism of their coding genes. Presence of nucleotide substitutions in certain loci leads to formation of different (from the point of view of metabolic rate) phenotypes of these enzymes (normal, slow, intermediate, fast). Thus, it is possible to predict the phenotype based on the genotype. Genetic testing of CYP2C19 and CYP2D6 in prescribing selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) is included in the Recommendations of the Consortium of Clinical Pharmacogenetics Implementation (CPIC, USA) (Hicks J, Sangkuhl K, Swen J et al; Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul; 102(1):37-44, Hicks JK, Bishop JR, Sangkuhl K et al; Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, Clin Pharmacol Ther. 2015 Aug; 98(2): 127-34). Given method enables detecting the following polymorphic markers in the genes: CYP2C19 *1/*2/*3/*17 (rs4244285, rs4986893, rs12248560) and CYP2D6 *1/*3/*4/*10/*41 (rs35742686, rs3892097, rs1065852, rs28371725). Determination of gene polymorphism enables to select the preparation and its dose effectively when prescribing antidepressant therapy.

EFFECT: invention makes it possible to perform analysis in short term and with low material costs.

1 cl, 2 dwg, 4 ex